Searched for
SEMAGLUTIDE APPLICATION
Dr Reddy's gets nod to roll out generic oral semaglutide drug"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to ...- Social media is abuzz with weight-loss drug retatrutide and longevity goals. What is the drug all about?A new weight-loss drug, retatrutide, is generating excitement. This investigational medicine targets three hormone receptors, offering a po...
- Govt orders safety review of popular weight-loss drugs amid rising demandIndian authorities are increasing vigilance on popular weight loss drugs. Indian Pharmacopoeia Commission will now compile reports on adver...
- Centre steps up oversight on GLP-1 drugs amid concerns over 'improper' practicesIndia's drug regulator is increasing oversight of GLP-1 weight loss drugs. Inspections across 49 entities revealed violations like unauthor...
- DCGI intensifies crackdown on GLP-1 drug misuse, sales and misleading adsIndia's drug regulator is cracking down on illegal sales and promotion of GLP-1 weight loss drugs. Inspections are underway across the coun...
- Strides Pharma to acquire Sandoz branded generics portfolio to expand Africa businessStrides Pharma Science is preparing to enhance its presence in Sub-Saharan Africa by acquiring branded generic products from Sandoz AG, wit...
- Govt cautions pharma cos against surrogate ads for promoting GLP-1 drugsWeight loss drug risks: The government has warned of strict regulatory action against those found using surrogate advertising to promote GL...
- The promise of EU-India FTA for Indian patients: A case for price regulationThe EU-India FTA promises cheaper drugs and medical devices, but India's regulatory framework may hinder patient benefits. Current pricing ...
- Dr Reddy's shares jump 5% despite 14% YoY fall in Q3 profit. Should you buy, sell or hold?Dr Reddy's shares: The company posted a 14% year-on-year decline in consolidated net profit to Rs 1,210 crore.
- Dr Reddy's Laboratories Q3 Results: Profit falls 14% YoY to Rs 1,210 crore, revenue up 4%Dr Reddy’s Laboratories reported a 14% YoY drop in Q3 net profit to Rs 1,210 crore, even as revenue rose 4% to Rs 8,727 crore. Lower margin...
- Future diabetes care seen leaning towards GLP-1 drugsThe diabetes treatment landscape in India is on the brink of transformation. Innovative GLP-1 medications are set to redefine therapy stand...
- Novo Nordisk shares jump 10% after US approves Wegovy pillNovo Nordisk shares jumped 10% on Tuesday after the U.S. Food and Drug Administration approved its weight-loss pill, giving the Danish dru...
- Novo Nordisk Stock Share Price Today: Why company's shares are down? Here's Alzheimer drug’s trial outcome, stock market impact, analysts insightsNovo Nordisk stock share price today fell after the company announced that semaglutide, used in Ozempic and Wegovy, failed to slow Alzheime...
- Dr Reddy’s Laboratories shares fall over 1% on Q2 results. Should you buy, sell or hold?Despite an uptick in profits, Dr Reddy's Laboratories experienced a decline in share value. Analysts continue to express optimism, keeping ...
- Can DRL’s new product launches offset the slowdown in Revlimid sales?Dr Reddy's Laboratories saw a high single-digit revenue increase in Q3, driven by India, emerging, and European markets, despite a muted US...
- Torrent Pharmaceuticals plans Semaglutide rollout post patent expiryTorrent Pharmaceuticals is gearing up to launch both oral and injectable versions of semaglutide, the weight loss drug, following the expir...
- Dr Reddy's plans to launch generic of Novo's weight-loss drug next year, CEO saysDr. Reddy's Laboratories intends to introduce a more affordable generic version of Novo Nordisk's popular weight-loss medication, Wegovy, i...
- No #iding behind #ashtags: Brand cultures must evolve as laws, ethics and sharper consumer awareness demand transparencyIn today's digital age, brands are facing increasing pressure to be transparent. Recent incidents, like the Air India crash and concerns ov...
- Cipla Q2 hit by seasonal chill, but investors need not worryCipla's September-quarter performance saw a 5.6% increase in consolidated net sales and a 15% rise in net profit despite slow seasonal grow...
- Weight-loss medicines: Biocon eyes a $100 billion jackpot with weighty pivotWeight-loss drugs: Biocon Ltd. is shifting focus to anti-obesity therapies as patents for key medications expire, leading to a surge in gen...
Load More
